

**Cogstate Limited**

ABN 80 090 975 723

Level 32

367 Collins Street

Melbourne, Vic, 3000

Australia

**P** +61 3 9664 1300**F** +61 3 9664 1301**W** [cogstate.com](https://cogstate.com)

# ASX Announcement

**23 June 2025**

## Investor Insights Series

Cogstate Ltd (ASX:CGS) today advises investors it will host its first webinar as part of its Investor Insights Series on Wednesday 25<sup>th</sup> June at 9.00am AEST (US Tuesday 24<sup>th</sup> June at 7.00pm EST).

**Driving Innovation in CNS Trials: The Cogstate-Medidata Partnership and the Future of Central Nervous System Research** features presentations from Medidata Chief Executive Officer Anthony Costello, Cogstate Chief Science Officer Pam Ventola, and Cogstate Executive Vice President Clinical Trials Rachel Colite.

The webinar hosted by Cogstate Chief Executive Officer Brad O'Connor will spotlight the dynamic partnership between Cogstate and Medidata, both recognised leaders in clinical trial technology and cognitive assessment. Attendees will discover how this collaboration is driving innovation and elevating outcomes in Central Nervous System disease research covering Medidata's advanced clinical trial platform, Cogstate's deep expertise in cognitive and clinical assessment, and the significant value their integrated approach delivers to sponsors, researchers, and patients alike.

Register now [here](#)

Cogstate's Investor Insights Series is a series of in-person and virtual events across Australia and the US, designed to expand investor reach, elevate the positioning and understanding of Cogstate, and engage better with existing shareholders and new investors.

The second webinar **Unlocking Alzheimer's Breakthroughs: Enabling Better Data-driven Decisions to Advance Drug Approvals** is also now open for registration and will be held on Tuesday 5 August at 9am AEST (US Monday 4<sup>th</sup> August at 7.00pm EST). This webinar will explore recent advancements in Alzheimer's disease therapeutics, the evolving role of biomarkers and cognitive assessments, and Cogstate's central position in supporting clinical trials and commercialisation.

Register now [here](#)

## Other Upcoming Dates

To stay up to date, sign up to the Cogstate Investor Hub: <https://investors.cogstate.com>

- Friday 22nd August 2025 at 9am AEST  
Webinar: **Cogstate Full Year FY25 Results**
- Thursday 16 October 2025 at 11am AEST  
**Annual General Meeting of Shareholders (Virtual and in person – Melbourne)**
- Friday 7th November 2025 from 9am-2pm AEDT  
**Shareholder Day (in-person): Melbourne**

This announcement was authorised for release by Cogstate Ltd CEO, Brad O'Connor.

---

### About Cogstate

Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company's clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform patients and save physician time. In this market, Cogstate has partnered with pharmaceutical company, Eisai, to distribute Cogstate assessments in the USA & Asia. For more information, please visit [www.cogstate.com](http://www.cogstate.com).

### For further information contact:

Brad O'Connor, Chief Executive Officer, [boconnor@cogstate.com](mailto:boconnor@cogstate.com)

---

### Important Notices

#### *Past performance*

Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past, present or future.

#### *Future performance and forward-looking statements*

This announcement contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its customers which are influenced by factors that are outside of Cogstate's control.

Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.